News from decision resources A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 28, 2014, 11:30 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies

 Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in...

Aug 27, 2014, 13:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials

 Decision Resources Group finds that physicians surveyed across six different specialties (medical oncology, hematology-oncology, rheumatology,...

Aug 27, 2014, 11:35 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Population Health Management Will Expand to More Type 2 Diabetes Patients

 Decision Resources Group finds that surveyed managed care organizations (MCOs), endocrinologists and primary care physicians (PCPs) anticipate...

Aug 27, 2014, 11:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Memphis-area Health Systems Turn Attention to Clinical Integration

Decision Resources Group finds that the intense physician acquisition activity that characterized the Memphis health system and hospital sector in...

Aug 26, 2014, 13:05 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

GlaxoSmithKline/Theravance's Anoro Ellipta is Most Likely to Replace Boehringer Ingelheim's Spiriva Among COPD Patients, According to U.S. Pulmonologists

Decision Resources Group finds that two-thirds of surveyed pulmonologists indicate that Boehringer Ingelheim's Spiriva is the agent most likely to...

Aug 21, 2014, 11:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms

 Decision Resources Group finds that, for the treatment of COPD,  physicians in Brazil and Mexico manage to follow clinical guidelines and...

Aug 21, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify

 Decision Resources Group finds that the asthma market in Brazil and Mexico currently faces severe coverage restrictions. The uptake of several...

Aug 20, 2014, 12:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Payers Exert Cost Controls on High-Cost Biologics to Treat Autoimmune Conditions

Decision Resources Group finds that surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments of...

Aug 20, 2014, 10:10 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023

 Decision Resources Group finds that the Japanese electrophysiology (EP) mapping and ablation device market will expand through 2023 as...

Aug 20, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market

 Decision Resources Group finds that the vascular access device market in Brazil, Russia, India and China (BRIC) was valued at approximately...

Aug 19, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Nearly Half of Surveyed Specialists Expect to Prescribe Gilead's Sofosbuvir/Ledipasvir Regimen Near-Term for Hepatitis C Infections

 Decision Resources Group finds that, for the treatment of hepatitis C virus (HCV) infections, 40 percent of surveyed HCV treating specialists...

Aug 18, 2014, 11:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Decision Resources Group Triples Coverage On U.S. Longitudinal Patient Claims Data Analytics

 Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians'...

Aug 18, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Xeljanz's Label Extension to Include Reduction of Radiographic Progression of Structural Joint Damage in RA Has Positively Impacted U.S. Rheumatologists' Perceptions of This Agent

 Decision Resources Group finds that the FDA approval of Pfizer's supplemental New Drug Application for Xeljanz in February 2014 to include the...

Aug 14, 2014, 12:15 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

U.S. and European Soft Tissue Repair Device Markets Will Expand Modestly In Line With Large Hernia Repair Device Market

 Decision Resources Group finds that the soft tissue repair device markets in the United States and Europe will expand slightly through 2022....

Aug 14, 2014, 11:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Physician-Reported Patient Share for Regeneron's Eylea Has Now Stabilized Following Significant Increases after Its U.S. Launch for Wet Age-Related Macular Degeneration

 Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular...

Aug 13, 2014, 11:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Improving Outlook in the U.S. Market is Due to Specialty Product Opportunities and Broader Patient Access with Implementation of the Affordable Care Act and Expansion of Medicaid

Decision Resources Group finds that the outlook for the pharmaceutical market in the United States is becoming more favorable, as the size of the...

Aug 13, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics

 Decision Resources Group finds that in the unipolar depression* market, the expanding use of two recently approved...

Aug 12, 2014, 13:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Changes Wrought by Affordable Care Act Lead to Surge in Private Exchanges

 Decision Resources Group finds that interest in private exchanges has sharply increased as the Affordable Care Act has gotten officially...

Aug 11, 2014, 16:55 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

The Asia Pacific Transcatheter Embolization and Occlusion Device Market Will Be Driven By the Adoption of Flow-Diverting Devices and Radioembolization Spheres

 Decision Resources Group finds that the Asia Pacific market for transcatheter embolization and occlusion (TEO) devices—including...

Aug 11, 2014, 10:00 ET
Decision Resources Group Logo.  (PRNewsFoto/Decision Resources Group)

Imatinib And Sunitinib Will Continue To Dominate Patient Share In The Patient Populations That They Are Approved For Through 2023

 Decision Resources Group finds that the treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through...